We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...
Valuation and recent performance snapshot Structure Therapeutics (GPCR) has drawn attention after recent trading moves, ...
Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...
Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Outperform recommendation. As of February 19, ...
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand ...
Fintel reports that on December 11, 2025, Jefferies maintained coverage of Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) with a Buy recommendation. As of December 6, 2025, the ...
Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...
Stocktwits on MSN
VKTX vs. GPCR: Which obesity drug developer does Wall Street see with the bigger upside?
Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. ・Structure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results